Inhibition of Aspirin-Induced Gastrointestinal Injury: Systematic Review and Network Meta-Analysis

Wan-tong Zhang†, Miao-ran Wang†, Guo-dong Hua†, Qiu-yan Li†, Xu-jie Wang†, Rui Lang*, Wei-liang Weng†, Chun-miao Xue† and Bao-chen Zhu†

1Institute of Clinical Pharmacology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 2Department of Endocrinology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 3Department of Pharmacy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China, 4National Clinical Research Center for Chinese Medicine Cardiology, Beijing, China, 5Department of Nephrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China

Background: Administration of aspirin has the potential for significant side effects of gastrointestinal (GI) injury mainly caused by gastric acid stimulation, especially in long-term users or users with original gastrointestinal diseases. The debate on the optimal treatment of aspirin-induced gastrointestinal injury is ongoing. We aimed to compare and rank the different treatments for aspirin-induced gastrointestinal injury based on current evidence.

Methods: We searched PubMed, EMBASE, Cochrane Library (Cochrane Central Register of Controlled Trials), and Chinese databases for published randomized controlled trials (RCTs) of different treatments for aspirin-induced gastrointestinal injury from inception to 1 May 2021. All of the direct and indirect evidence included was rated by network meta-analysis under a Bayesian framework.

Results: A total of 10 RCTs, which comprised 503 participants, were included in the analysis. The overall quality of evidence was rated as moderate to high. Eleven different treatments, including omeprazole, lansoprazole, rabeprazole, famotidine, geranylgeranylacetone, misoprostol, ranitidine bismuth citrate, chili, phosphatidylcholine complex, omeprazole plus rebamipide, and placebo, were evaluated in terms of preventing gastrointestinal injury. It was suggested that omeprazole plus rebamipide outperformed other treatments, whereas geranylgeranylacetone and placebo were among the least treatments.

Conclusion: This is the first systematic review and network meta-analysis of different treatments for aspirin-induced gastrointestinal injury. Our study suggested that omeprazole plus rebamipide might be considered the best option to treat aspirin-induced gastrointestinal injury. More multicenter, high quality, large sample size randomized controlled trials will confirm the advantages of these medicines in the treatment of aspirin-induced gastrointestinal injury in the future.

Keywords: aspirin, gastrointestinal injury, healthy subject, network meta-analysis, randomized controlled trials

Abbreviations: AE, adverse event; COX, cyclooxygenase; GI, gastrointestinal; H2RA, histamine 2 receptor antagonist; NMA, network meta-analysis; PGE2, prostaglandins E2; PGH2, prostaglandin H2; PGJ2, prostaglandins I2; PPI, proton pump inhibitor; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analysis; RCT, randomised controlled trials; SUCRA, Surface under the Cumulative Ranking curve.
INTRODUCTION

Aspirin is a well-known baseline antiplatelet agent, serving as the primary and secondary treatment as well as the treatment of ischemic stroke, acute myocardial infarction, transient ischemic attack, acute coronary syndrome, and peripheral artery diseases (A. J. Hermosillo and Spinler, 2008). However, many studies have shown that the administration of aspirin has the potential for significant side effects of gastrointestinal (GI) symptoms including mucosal lesions, bleeding or peptic ulcers, especially in long-term users or users with origin gastrointestinal diseases (R. Guthrie, 2011). The aspirin-induced gastric injury is a chronic inflammation mainly caused by gastric acid stimulation, as aspirin break the gastric mucosal barrier; gastric acid is capable of breaking the mucosal epithelial cells directly, causing inflammation, bleeding, and gastric ulcer. However, the mechanism of aspirin-induced small bowel injury has remained incompletely understood; its occurrence involves intestinal microorganism, bile and other stimulating factors, which is more complex than the gastric injury caused by aspirin (Washio, et al., 2016; Wallace, 2012). Therefore, there are no guideline recommendations for the treatment of aspirin-induced gastrointestinal injury.

Medications such as proton pump inhibitors (PPIs), histamine 2 receptor antagonists (H2RAs), misoprostol, and alendronate are used clinically to prevent aspirin-induced gastrointestinal injury. Recent randomized controlled trials (RCTs) have demonstrated that these treatments have high therapeutic potential effects for aspirin-induced gastrointestinal injury. However, it is difficult to directly rank the efficacy and safety of the treatments due to the limitations of study design and scale.

Comparing to conventional meta-analysis, network meta-analysis (NMA) offers more advantages, which has been increasingly advocated in medical research, as it provides more comprehensive analytical evidence for selecting the optimal treatment by directly and indirectly evaluating different intervention models (Nikolakopoulou et al., 2018). To address this knowledge gap, we conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) of all the medications used in aspirin-induced gastrointestinal injury to evaluate their relative efficacy and safety.

METHODS

Our systematic review and NMA manuscript was written in accordance with the Cochrane Handbook (Higgins et al., 2020). Reporting was consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) extension statement for reporting systematic reviews incorporating NMA (Guise et al., 2017).

Data Sources and Searches

We searched PubMed, EMBASE, Cochrane Library (Cochrane Central Register of Controlled Trials), and two Chinese databases (China National Knowledge Internet database and China Wanfang database) for citations published in any language from inception to 1 May 2021. We used combinations of MeSH terms and text words around “aspirin,” “acetylsalicylic acid,” “gastrointestinal injury,” “gastrointestinal lesions,” “peptic ulcer,” “bleeding,” “perforation,” “obstruction,” “healthy people,” “healthy subjects,” “randomized controlled trial,” and “clinical trial.” Additional studies were derived from screening the reference lists of included RCTs and previous systematic reviews. We also searched trial registers like ClinicalTrials.gov, iSCTRN, and OpenTrials.net to identify any unpublished or ongoing trials and contacted the researchers to ask about unpublished studies.

Eligibility Criteria

We included the RCTs with the following criteria: 1) RCTs inhibiting aspirin-induced gastrointestinal injury with medication in healthy people; 2) RCTs reporting number of people with gastrointestinal lesions, with or without safety outcome; 3) minimum sample size no less than 20.

We excluded the RCTs with the following criteria: 1) RCTs with significant flaws, incomplete or wrong results; 2) dissertations and conference abstracts; and 3) RCTs with the participant numbers in the smaller group less than 20. Besides, we excluded observational, cross-sectional, case series, or qualitative studies.

Data Extraction and Quality Assessment

Two independent authors (Wan-tong Zhang and Bao-chen Zhu) assessed all RCTs for eligibility and extracted data and assessed study quality. Disagreements were resolved by consensus-based discussion. The full-text articles were downloaded and the same inclusion criteria were used to decide whether to include or exclude at this stage. The average age and sex ratio of patients, grouping, intervention measures and outcome indicators were recorded. Each reviewer independently carried out the quality assessment of each selected article, assessed the completeness of the data extraction, and confirmed the quality rating to reduce bias.

Three authors (Wan-tong Zhang, Bao-chen Zhu, and Miao-ran Wang) evaluated all the included RCTs. Any disagreement was solved through discussion, mutual consensus, and rechecking of the article. For the RCTs which were included, the Cochrane risk-of-bias tool was used to assess risk of bias (Sterne et al., 2019), including selection bias (random sequence generation/allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attribution bias (incomplete outcome data), reporting bias (selective outcome reporting), and other possible sources of bias. In this way, all articles selected for inclusion in the review were graded under the categories of low, high, or unclear risk of bias.

The efficacy outcome was the number of individuals diagnosed with gastrointestinal injury after taking aspirin. Safety assessments included adverse events (AEs).

Data Synthesis

For further evaluation of gastrointestinal protecting medications simultaneously, a network meta-analysis was used to synthesize...
the study effect sizes (both direct and indirect comparisons). Heterogeneity across individual studies was estimated by the Cochran Q test (Chi-squared) and Higgins I-squared inconsistency statistic. If there was no significant heterogeneity ($p > 0.05$, I-squared <50%), a fixed-effects model was used. Otherwise, a random-effects model was used. Moreover, the analysis of ranking probabilities and the Surface under the Cumulative Ranking curve (SUCRA) were used to explore the probabilities of each treatment being ranked the best. The SUCRA value, expressed as a percentage, is one of the best choices for indicating the relative probability of intervention. Inconsistency in the network was evaluated using the deviance information criterion (DIC) between the consistent and inconsistent models. If the DIC difference was within 3, the data were generally considered to be consistent. Once considerable heterogeneity ($p < 0.05$, I-squared>50%) was found in pairwise meta-analyses, we will conduct a sensitivity analysis; that is, we will remove those studies that lead to high heterogeneity indirect comparisons or introduced statistical inconsistency in the NMA. All data were analyzed by using the R 3.6.3 software and Review Manager version 5.4.

RESULTS

Study Screening

By searching five different electronic databases and manual reference searching, 241 relevant publications were found after removing duplications and unrelated studies. Relevant articles were further selected by reading the full texts. By excluding publications that contained noneligible data, had unsuitable comparator arms, and were not clinical trials and nonrandomized trials, 10 articles were included. Figure 1 shows the detailed steps of the literature selection process.

Study Characteristics and Network Plots

In total, 10 trials were included in the NMA, and their basic characteristics are presented in Table 1. A network of eligible comparisons for the multiple-treatment meta-analysis was constructed (Figure 2). These RCTs compared eleven treatments, namely omeprazole, lansoprazole, rabeprazole, famotidine, ranitidine bismuth citrate, misoprostol, ranitidine bismuth citrate, chili, phosphatidylcholine complex, omeprazole plus rebamipide, and placebo.

Table 1 summarizes the 10 trials published between 1992 and 2011. Most trials (8 of 10) were two-group studies, and only two trials had three or more groups. Overall, 503 patients were randomly assigned to one or two of the 10 gastrointestinal protecting medications or the placebo and included in the NMA. These RCTs compared 10 treatments, including omeprazole plus rebamipide (Kazuhiro et al., 2011), famotidine (Masafumi et al., 2011; Sugimoto et al., 2012), lansoprazole (Bergmann et al., 1992; Masafumi et al., 2011; Sugimoto et al., 2012), rabeprazole (Sugimoto et al., 2012), phosphatidylcholine complex (Byron et al., 2011), geranylgeranylacetone (Akiko et al., 2010), misoprostol (M. T. Donnelly et al., 2000), chili (K.G. Yeoh et al., 1995), omeprazole (James. M. Scheiman et al., 1994; Kazuhiro et al., 2011), and ranitidine bismuth citrate (N. Hudson et al., 1993). The mean study sample size was 50 participants, ranging from 20 to 181 participants. The treatment duration was less than 14 days in the vast majority of the subjects (80%).

Quality of Trials

The quality of the studies included in this NMA is shown in Figure 3. In terms of random sequence generation and allocation concealment, 30% (3/10) were considered to be low risk. 90% (9/10) were rated as “low risk of bias” in terms of blinding of participants and personnel, and 70% (7/10) of the studies have the confirmation that the outcome indicators were not easily affected by subjective factors. All of the studies reported complete outcome data. 90% (9/10) of the studies were rated as “low risk of bias” in terms of selective reporting and 70% (7/10) of the studies were rated as “low risk of bias” in terms of other bias.

Results of Meta-Analyses

Figure 4 shows the results of the head-to-head comparisons for the gastrointestinal injury. The treatments are reported according to their gastrointestinal injury ranking. Treatment at the top left corner ranks first, while the one at the bottom right corner ranks last. We estimated SUCRA values to rank all interventions for their gastrointestinal injury ranking. The treatments are reported according to other characteristics are presented in Table 1.
| Study                  | Country  | Intervention group | Control group | | Treatment | Treatment | Treatment duration (days) | Outcomes | Side effect | Conclusion |
|------------------------|----------|--------------------|---------------|-------------|-----------|--------------------------|-----------|-------------|------------|
| Kazuhiro et al. (2011) | Japan    | 11 Aspirin (100 mg/day) + omeprazole (20 mg/day) + rebamipide (300 mg/day) | 11 Aspirin (100 mg/day) + omeprazole (20 mg/day) | | 28 | 1. Number of participants with gastrointestinal lesions 2. Side effect | None | The combination use of rebamipide and omeprazole is superior to omeprazole |
| Sugimoto et al. (2012) | Japan    | 15①Aspirin (100 mg/day) + famotidine (40 mg/day) ②Aspirin (100 mg/day) + lansoprazole (15 mg/day) ③Aspirin (100 mg/day) + rabeprazole (10 mg/day) | 15 Aspirin (100 mg/day) | | 7 | 1. Number of participants with gastrointestinal lesions 2. Side effect | None | Lansoprazole and rabeprazole are superior to famotidine |
| Byron et al. (2011)   | USA      | 90 Aspirin–phosphatidylcholine complex (325 mg/day) | 91 Aspirin (325 mg/day) | | 7 | 1. Number of participants with gastrointestinal lesions 2. Side effect | None | Aspirin–phosphatidylcholine complex is superior to placebo |
| Masafumi et al. (2011) | Japan    | 15①Aspirin (100 mg/day) + famotidine (40 mg/day) ②Aspirin (100 mg/day) + lansoprazole (15 mg/day) | 15 Aspirin (100 mg/day) | | 7 | 1. Number of participants with gastrointestinal lesions 2. Side effect | None | Lansoprazole is superior to famotidine |
| Akiko et al. (2010)   | Japan    | 10 Aspirin (100 mg/day) + geranylgeranylacetone (150 mg/day) | 10 Aspirin (100 mg/day) | | 7 | 1. Number of participants with gastrointestinal lesions 2. Side effect | None | No significant difference between the two groups |
| M. T. Donnelly et al. (2000) | UK | 16 Aspirin (300 mg/day) + misoprostol (100 μg/day) | 16 Aspirin (300 mg/day) | | 28 | 1. Number of participants with gastrointestinal lesions 2. Side effect | 3 in intervention group; 6 in control group | Misoprostol is superior to placebo |
| Yeoh et al. (1995)    | Singapore | 18 Aspirin (600 mg/day) + chili | 18 Aspirin (600 mg/day) | | 1 | 1. Number of participants with gastrointestinal lesions 2. Side effect | None | Chili is superior to placebo |
| Scheiman et al. (1994) | USA      | 20 Aspirin (2,600 mg/day) + omeprazole (40 mg/day) | 20 Aspirin (2,600 mg/day) | | 14 | 1. Number of participants with gastrointestinal lesions 2. Side effect | 16 in intervention group; 7 in control group | Omeprazole is superior to placebo |
| Hudson et al. (1993)  | UK       | 21 Aspirin (1,800 mg/day) + ranitidine bismuth citrate (800 mg/day) | 22 Aspirin (1,800 mg/day) | | 5 | 1. Number of participants with gastrointestinal lesions 2. Side effect | None | Ranitidine bismuth citrate is superior to placebo |
| Bergmann et al. (1992) | France   | 12 Aspirin (1,000 mg/day) + lansoprazole (30 mg/day) | 12 Aspirin (1,000 mg/day) | | 7 | 1. Number of participants with gastrointestinal lesions 2. Side effect | None | Lansoprazole is superior to placebo |
Ranitidine bismuth citrate was associated with a significant reduction in the risk of gastrointestinal injury in pairwise comparisons with chili (OR: 0.00, 95% CI: 0.00–0.91), rabeprazole (OR: 0.00, 95% CI: 0.00–0.73), famotidine (OR: 0.00, 95% CI: 0.00–0.12), misoprostol (OR: 0.00, 95% CI: 0.00–0.15), phosphatidylcholine complex (OR: 0.00, 95% CI: 0.00–0.08), and placebo (OR: 0.00, 95% CI: 0.00–0.02). Omeprazole was associated with a significant reduction in the risk of gastrointestinal injury in pairwise comparisons with chili (OR: 0.00, 95% CI: 0.00–0.38), rabeprazole (OR: 0.00, 95% CI: 0.00–0.51), famotidine (OR: 0.00, 95% CI: 0.00–0.08), misoprostol (OR: 0.00, 95% CI: 0.00–0.10), phosphatidylcholine complex (OR: 0.00, 95% CI: 0.00–0.05) and placebo (OR: 0.00, 95% CI: 0.00–0.02). Lansoprazole was associated with a significant reduction in the risk of gastrointestinal injury in pairwise comparisons with placebo (OR: 0.01, 95% CI: 0.00–0.11). In the direct meta-analysis, lansoprazole (OR, 36.50; 95% confidence interval [CI], 8.02–166.22) was also associated with the reduction in the risk of gastrointestinal injury compared to placebo (Figure 5).

We further ranked all treatments according to SUCRA; Figure 6 presented all treatments ordered by their probability to be the best treatment in terms of gastrointestinal injury. It was suggested that omeprazole plus rebamipide, ranitidine bismuth citrate, and omeprazole outperformed other treatments, whereas geranylgeranyacetone and placebo were among the least treatments.

The inconsistency in the network for the nine interventions was summarized under consistency and inconsistency assumptions (Supplementary Tables); the difference of DIC
between two models was no more than three, which means the results are generally considered consistent. In the heterogeneity analysis, global I-squared did not identify any heterogeneity across the studies (Supplementary Tables; global I^2 = 16.21).

DISCUSSION

Aspirin-induced gastrointestinal damage limits its regular use. PPI, H2RAs, misoprostol, alendronate, and some other gastrointestinal protecting medications are widely used in clinical practice for preventing the injury; however, there are no guideline recommendations for the injury. Therefore, identifying the treatment with the best safety and efficacy is important. To the best of our knowledge, there is currently no comparison of multiple interventions for treating aspirin-induced gastrointestinal injury; this is the first systematic review and network meta-analysis investigating different treatments for aspirin-induced gastrointestinal injury. Our study suggested that the combination of omeprazole and rebamipide was potentially the preferred intervention.

The mechanism of aspirin-induced gastrointestinal injury is usually considered to be divided into two parts: direct injury and indirect injury. The indirect mechanism of damage to the gastrointestinal mucosa by aspirin is the nonreversible inactivation of cyclooxygenase (COX), which inhibits the conversion of arachidonic acid to prostaglandin H2 (PGH2) in platelets (Hart and Bailey, 2002), subsequently affecting the production of prostaglandins PGE2 and PGI2. The decreased secretion of PGE2 decreases gastric mucus and HCO3-secretion and reduces gastrointestinal blood flow (Takeuchi, et al., 2015). The decreased secretion of PGI2 also decreases gastrointestinal lower blood flow (Harada et al., 1999). The limited energy caused by the lower blood flow reserved in the gastrointestinal mucosa makes it very sensitive to ischemia and hypoxia. It might cause damage to epithelial cells of the gastrointestinal mucosa, reduce...
mucosal barrier function, increase permeability and the susceptibility to endotoxin and bacterial attack. Another indirect mechanism of damage is that aspirin could affect intestinal flora, in particular, Gram-negative bacteria. It stimulates the immune system characterized by Toll-like receptor 4 and finally induces inflammation (Otani et al., 2017). The main ways in which aspirin causes direct gastrointestinal damage include 1) disrupting the hydrophobicity of mucus $\text{HCO}_3^-$ protective layer of the gastric mucosa (Goddard and Hills, 1987); 2) damaging the gastrointestinal mucosal epithelial cells, including inducing oxidative stress damage to the gastrointestinal mucosal epithelial cells, elevating malondialdehyde concentration and inducing apoptosis in the gastrointestinal mucosal epithelial cells (Hernandez et al., 2016); and 3) disrupting the permeability of the gastrointestinal tract and causing inflammation (Lai et al., 2015). In summary, aspirin-induced gastrointestinal damage may be caused by a combination of inhibition of mucus secretion, inhibition of mucosal blood flow, oxidative stress damage, and inflammation, which is observed in our previous preclinical research (Zhu, et al., 2018). In such cases, inhibition of gastric acid production alone may not fundamentally inhibit aspirin-induced gastrointestinal injury. The treatment should be considered to elevate mucosal blood flow, reduce inflammatory infiltration, and promote mucus production at meantime. In animal experiments, rebamipide inhibited the infiltration of inflammatory cells in the gastric mucosa and increased the amount of gastric mucus, gastric mucosal blood flow, and gastric mucosal prostaglandin content. However, rebamipide showed no inhibitory effect on stimulating gastric acid secretion (Arakawa et al., 2005). Therefore, the combination of rebamipide with PPIs whose main effect is to inhibit gastric acid secretion can mechanistically inhibit aspirin-induced gastrointestinal injury.

H2RA and PPI are also used in clinical practice against aspirin-induced gastrointestinal injury. The results suggest that ranitidine bismuth citrate, omeprazole, and lansoprazole showed greater effectiveness than placebo. Ranitidine bismuth citrate is a combination drug of H2RA with bismuth citrate. The gastroprotective effects of ranitidine bismuth citrate include inhibiting gastric acid secretion (Tanaka, et al., 1996), inhibition of pepsin activity (Tay, et al., 1990), binding to ulcers (Koo et al., 1982), stimulation of prostaglandin synthesis and bicarbonate secretion (Konturek et al., 1987; Mertz-Nielsen et al., 1991), antibacterial activity (Manhart, 1990), and binding to mucus (Lambert, 1991). PPIs could inhibit gastric acid secretion and pepsin activity (El et al., 2018). Although not as good as the combination of rebamipide and PPIs, the use of PPI and ranitidine bismuth citrate alone can also be effective clinically.

In addition to the efficacy, safety is also an important issue in the treatment of aspirin-induced gastrointestinal injury. Clinicians have a responsibility to ensure that subjects were informed about the potential adverse drug reactions. The results showed that the combination of aspirin and protective treatments for gastrointestinal injury showed less side effects. Adverse events just happened in two treatments which are diarrhoea, dyspepsia, headache, aphthous ulcer, tinnitus, nausea, heartburn, abdominal pain, skin rash, and facial puffiness.

Compared with previous conventional pairwise meta-analyses, several merits of this study need to be highlighted.
First, this study used network meta-analysis to explore the relative benefits of different treatments for aspirin-induced gastrointestinal injury and inform related clinical guidelines. The Bayesian model used in our study is currently the most applicable approach for multiple-intervention network meta-analysis, which could address the absence of direct comparison and reveal a favorable intervention by ranking analysis. Second, our literature search was as comprehensive as possible, which not only retrieved electronic databases commonly used in Chinese and English but also retrieved references from the reference lists of included RCTs and previous systematic reviews. However, this study also has some limitations, such as the uneven chronological distribution of the included literature, while the doses of aspirin used in some 1990s literature are too large compared to the current treatment regimen.

As a result, this comprehensive search strategy for the retrieval of the maximum number of available published trials and a predesigned inclusion criterion ensured the lowest possible degree of heterogeneity. There are several implications and considerations related to these findings. First, this study was conducted in healthy subjects to provide clinical indications for subsequent long-term users of aspirin. Second, this paper includes a variety of drugs that may play a role in prevention and treatment of aspirin-induced gastrointestinal injury, including novel drugs, to inform future clinical studies and guideline development.

CONCLUSION

This is the first systematic review and network meta-analysis of different treatments for aspirin-induced gastrointestinal injury. The findings from this network meta-analysis represent the most comprehensive analysis of the available evidence. Our findings suggested that omeprazole plus rebamipide might be considered the best option to treat aspirin-induced gastrointestinal injury. Moreover, more multicenter, high quality, large sample size randomized controlled trials will confirm the advantages of different medicine in the treatment of aspirin-induced gastrointestinal injury in the future.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

All authors were involved in the planning of the study, literature review, interpretation of the findings, and manuscript preparation. W-tZ, B-cZ, and W-lW conceived and designed the study. B-cZ drafted the report. M-rW and W-tZ did the statistical analysis. All authors revised the report and approved the final version before submission.

FUNDING

The study was supported by the National Natural Science Foundation of China (82004125), Beijing University of Chinese Medicine (2020-JYB-XJSJJ-041), and the Academic Inheritance Studio of Weng Wei-liang.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.730681/full#supplementary-material

REFERENCES

Arakawa, T., Higuchi, K., Fujiwara, Y., Watanabe, T., Sasaki, E., Tominaga, K., et al. (2005). 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications. Dig. Dis. Sci. 50–S1. doi:10.1007/s10620-005-2800-9
Bergmann, J. F., Chassany, O., Simoneau, G., Lemaire, M., Segrestaa, J. M., Caulin, C., et al. (1992). Protection Against Aspirin-Induced Gastric Lesions by Lansoprazole: Simultaneous Evaluation of Functional and Morphologic Responses. Clin. Pharmacol. Ther. 52, 413–416. doi:10.1038/clpct.1992.164
Cryer, B., Bhatt, D. L., Lanza, F. L., Dong, J. F., Lichtenberger, I. M., Marathi, U. K., et al. (2011). Low-dose Aspirin-Induced Ulceration Is Attenuated by Aspirin-Phosphatidylcholine: A Randomized Clinical Trial. Am. J. Gastroenterol. 106, 272–277. doi:10.1038/ajg.2010.436
Donnelly, M. T., Goddard, A. F., Filipowicz, B., Morant, S. V., Shield, M. J., Hawkey, C. J., et al. (2000). Low-dose Misoprostol for the Prevention of Low-Dose Aspirin-Induced Gastroduodenal Injury. Aliment. Pharmacol. Ther. 14, 529–534. doi:10.1046/j.1365-2036.2000.00739.x
El, R. N., Lima, J. J., and Johnson, J. A. (2018). Proton Pump Inhibitors: From CYTP2C19 Pharmacogenomics to Precision Medicine. Expert Opin. Drug Metab. Toxicol. 14, 447–460. doi:10.1080/17425255.2018.1461835
Goddard, P. J., and Hills, B. A. (1987). Lichtenberger LM. Does Aspirin Damage Canine Gastric Mucosa by Reducing its Surface Hydrophobicity. Am. J. Physiol. 252 (3 Pt 1). G421–G430. doi:10.1152/ajpgi.1987.252.3.G421
Guise, J. M., Butler, M. E., Chang, C., Viswanathan, M., Pigott, T., and Tugwell, P. (2017). Complex Interventions Workgroup.AHRQ Series on Complex Intervention Systematic Reviews-Paper 6: PRISMA-CI Extension Statement and Checklist. J. Clin. Epidemiol. 90, 43–50. doi:10.1016/j.jclinepi.2017.06.016
Guthrie, R. (2011). Review and Management of Side Effects Associated with Antiplatelet Therapy for Prevention of Recurrent Cerebrovascular Events. Adv. Ther. 28, 473–482. doi:10.1007/s12325-011-0026-0
Harada, N., Okajima, K., Murakami, K., Isobe, H., and Liu, W. (1999). Gastric prostacyclin(PGI2) Prevents Stress-Induced Gastric Mucosal Injury in Rats Primarily by Inhibiting Leukocyte Activation. Prostaglandins Other Lipid Mediat 57 (5-6), 291–303. doi:10.1016/s0090-6980(98)00077-x
Hart, R. J., and Bailey, R. D. (2002). An Assessment of Guidelines for Prevention of Ischemic Storoke. Neurology 59 (7), 977–982. doi:10.1212/wnl.59.7.977
Herrerosillo, A. J., and Spiniel, S. A. (2008). Aspirin, Clopidogrel, and Warfarin: Is the Combination Appropriate and Effective or Inappropriate and Too Dangerous? Ann. Pharmacother. 42, 790. doi:10.1345/aph.1K591
Hernandez, C., Barrachina, M. D., Vallecillo-Hernandez, J., Alvarez, A., Ortiz-Masiá, D., Cosín-Roger, J., et al. (2016). Aspirin-induced Gastrointestinal...
Damage Is Associated with an Inhibition of Epithelial Cell Autophagy. *J. Gastroenterol.* 51 (7), 691–701. doi:10.1007/s00357-015-1137-1

Hudson, N., Murray, F. E., Cole, A. T., Turnbull, G. M., Lettis, S., Hawkey, C. J., et al. (1993). Ranitidine Bismuth Citrate and Aspirin-Induced Gastric Mucosal Injury. *Aliment. Pharmacol. Ther.* 7, 515–521. doi:10.1111/j.1365-2036.1993.tb00127.x

Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., et al. (2020). *Cochrane Handbook for Systematic Reviews of Interventions*. London, UK: Cochrane. Available at: www.training.cochrane.org/handbook.

Konturek, S. J., Bilski, J., Kwiecien, N., Obtulowicz, W., Kopp, B., and Oleksy, J. (1982). Selective Coating of Gastric Ulcer by Tripeptidum Dicitrat Bismuthate in the Rat. *Gastroenterology* 82, 864–870. doi:10.1016/s0016-5085(82)80247-3

Lai, Y., Zhong, W., Yu, T., Xia, Z. S., Li, J. Y., Ouyang, H., et al. (2015). Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury Through Accumulation of B-Catenin. *PLoS One* 10, e0132031. doi:10.1371/journal.pone.0132031

Hudson, N., Murray, F. E., Cole, A. T., Turnbull, G. M., Lettis, S., Hawkey, C. J., et al. (1993). Ranitidine Bismuth Citrate Causes Sustained Release of Gastric Mucosal Prostaglandin E2. *Aliment. Pharmacol. Ther.* 5, 127–133. doi:10.1111/j.1365-2036.1991.tb00013.x

Mertz-Nielsen, A., Steenberg, P., Neumark, T., Bukhave, K., and Rask-Madsen, J. (1991). Colloidal Bismuth Subcitrate Causes Sustained Release of Gastric Mucosal Prostaglandin E2. *Aliment. Pharmacol. Ther.* 5, 127–133. doi:10.1111/j.1365-2036.1991.tb00013.x

Mizukami, K., Murakami, K., Abe, T., Inoue, K., Uchida, M., Okimoto, T., et al. (2011). Aspirin-induced Small Bowel Injuries and the Preventive Effect of rebamipide. *World J. Gastroenterol.* 17, 5117–5122. doi:10.3748/wjg.v17.i36.s117

Nishino, M., Sugimoto, M., Kodaira, C., Yamade, M., Uotani, T., Shirai, N., et al. (2011). Preventive Effects of Lansoprazole and Famotidine on Gastric Mucosal Injury. *Clin. Gastroenterol. Hepatol.* 9, 809–815. doi:10.1016/j.cgh.2010.10.022

Zhu, B. C., Zhang, W. T., Lu, Y., Hu, S., Gao, R., Sun, Z., et al. (2018). Network Pharmacology-Based Identification of Protective Mechanism of Panax Notoginseng Saponins on Aspirin Induced Gastrointestinal Injury. *Biomed. Pharmacother.* 103, 159–166. doi:10.1016/j.biopha.2018.04.054

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhang, Wang, Hua, Li, Wang, Leng, Weng, Xue and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.